2018 ´ëÇѺÎÁ¤¸ÆÇÐȸ NOAC »ç¿ë Áöħ: Ưº°ÇÑ »óȲ¿¡¼ÀÇ ¾à¹° º¹¿ë(°ü»óµ¿¸ÆÁúȯ, ¿ë·® È¥µ¿½Ã, ½ÉÀ²µ¿ Àüȯ, ³úÁ¹Áß ¹ß»ý, ¾Ç¼ºÁ¾¾ç) ¹× ±âŸ
2018 Korean Heart Rhythm Society Guidelines for Non-Vitamin K Antagonist Oral Anticoagulants
¹Ú¿¹¹Î, ¹ÚÇü¿í, ÀÌÁ¤¸í, ¹ÚÁø±Ô, À̱âÈ«, ±èÁø¹è, ÀÌ¿µ¼ö, Á¤º¸¿µ,
¼Ò¼Ó »ó¼¼Á¤º¸
¹Ú¿¹¹Î ( Park Yae-Min )
°¡Ãµ´ëÇб³ ±æº´¿ø ½ÉÀå³»°ú
¹ÚÇü¿í ( Park Hyung-Wook )
Àü³²´ëÇб³º´¿ø ¼øȯ±â³»°ú
ÀÌÁ¤¸í ( Lee Jung-Myung )
°æÈñ´ëÇб³º´¿ø ½ÉÀå³»°ú
¹ÚÁø±Ô ( Park Jin-Kyu )
ÇѾç´ëÇб³ ¼¿ïº´¿ø ½ÉÀå³»°ú
À̱âÈ« ( Lee Ki-Hong )
Àü³²´ëÇб³º´¿ø ¼øȯ±â³»°ú
±èÁø¹è ( Kim Jin-Bae )
°æÈñ´ëÇб³º´¿ø ½ÉÀå³»°ú
ÀÌ¿µ¼ö ( Lee Young-Soo )
´ë±¸°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ½ÉÀå³»°ú
Á¤º¸¿µ ( Joung Bo-Young )
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø ½ÉÀå³»°ú
Abstract
Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative to vitamin K antagonists (VKAs) and have emerged as the treatment of choice in Korea. However, several questions remain regarding the optimal use of these agents in specific clinical situations. In this paper we discuss 1) patients with atrial fibrillation (AF) and coronary artery disease, 2) avoiding confusion with NOAC dosing across indications, 3) cardioversion in a patient treated with a NOAC, 4) AF patients who present with acute stroke while on NOACs, 5) NOACs in special situations, 6) anticoagulation in AF patients with a malignancy, and 7) optimizing VKA dose adjustments.
Å°¿öµå
Atrial fibrillation; Non-vitamin K antagonist oral anticoagulants; Guideline
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸